A diversity of clients. An abundance of solutions.
Consilium’s clients range from multi-billion-dollar corporations to smaller, privately held companies. Our recent focus has been supporting clients in preparing numerous Premarket Tobacco Product Applications (PMTAs) and Substantial Equivalence (SE) applications, as well as rapid turnaround scientific litigation support.
At Consilium we take pride in developing strong relationships with clients and understanding their unique needs so that we can build the right team of scientific experts to develop and implement quality solutions. Our global network of mostly doctoral-level scientists and clinicians includes expertise in nanotechnology, materials characterization, toxicology, pharmacology, epidemiology, chemistry, GMP, consumer research, regulatory engagement, post-market surveillance, literature reviews, statistics and more.
We develop and provide scientific and regulatory solutions and regularly engage with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada.
Consilium’s clients include tobacco, vaping and cannabis organizations ranging from multi-billion-dollar global corporations to smaller,
privately held companies.
Consilium’s mission is to be the leading provider of regulatory solutions for materials science, vaping, tobacco and cannabis products. This includes preparation of PMTAs, SEs, MRTPAs and TPMFs as well as other regulatory documents for the FDA, EMA and Health Canada.
Our emphasis is on potentially harm-reduced products.